SAN MATEO, Calif., Nov. 10 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that Anthony DiTonno, President and Chief Executive Officer, is scheduled to present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York City on Tuesday, November 11, 2008. Mr. DiTonno and Stephen Ghiglieri, Chief Financial Officer, will also be available to respond to questions during the breakout session immediately following the presentation.
Event: Rodman & Renshaw 10th Annual Healthcare Conference
Date: Tuesday, November 11, 2008
Time: 2:25 p.m. ET
Place: New York Palace Hotel, Holmes II (4th Floor)
The presentation will be webcast live and can be accessed by visiting the investor relations section of NeurogesX' website at http://www.neurogesx.com. The webcast will be archived for 15 days.
About NeurogesX, Inc.
NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the Company believes offers significant advantages over other pain therapies. NeurogesX submitted a new drug application (NDA) for NGX-4010 with the U.S. Food and Drug Administration (FDA) in October 2008 for PHN, which is subject to acceptance by the FDA. Additionally, a marketing authorization application (MAA) for NGX-4010 seeking approval for peripheral neuropathic pain is currently under review by the European Medicines Agency (EMEA).
NeurogesX' second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 is currently in Phase 1 development.
NeurogesX' early stage product pipeline includes pre-clinical compounds which are prodrugs of acetaminophen and various opioids. The company has evaluated these compounds in vitro and in vivo and is currently seeking development partners for these programs.
Safe Harbor Statement
This press release contains forward-looking statements for purposes of
the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX
disclaims any intent or obligation to update these forward-looking
statements, and claims the protection of the Safe Harbor for
forward-looking statements contained in the Act. Examples of such
statements include, but are not limited to, the potential markets for
NeurogesX' product candidates; the expected benefits of NeurogesX' product
candidates; and its plans with regard to seeking potential development
partners for its early stage product pipeline. Such statements are based on
management's current expectations, but actual results may differ materially
due to various risks and uncertainties, including, but not limited to,
NeurogesX' product candidates may have unexpected adverse side effects or
inadequate therapeutic efficacy; positive results in clinical trials may
not be sufficient to obtain FDA or European regulatory approval; any
regulatory approvals which are received may be limited to certain
indications; physician or patient reluctance to use NGX-4010 or NGX-1998,
if approved, or the inability of physicians to obtain sufficient
reimbursement for such procedures; potential alternative therapies;
maintaining adequate patent or trade secret protection without violating
the intellectual property rights of others; and other difficulties or
delays in, clinical development, obtaining regulatory approval, market
acceptance and commercialization of NeurogesX' product candidates and the
advantages of NeurogesX' product candidates over other pain therapies. For
further information regarding these and other risks related to NeurogesX'
business, investors should consult NeurogesX' filings with the Securities
and Exchange Commission.
NeurogesX, Inc. The Ruth Group
Stephen Ghiglieri Stephanie Carrington /
Chief Financial Officer Sara Ephraim (investors)
(650) 358-3310 (646) 536-7017 / 7002
Jason Rando (media)
|SOURCE NeurogesX, Inc.|
Copyright©2008 PR Newswire.
All rights reserved